Plavix May Be Next on FDA’s List of Drugs To Relabel with Genetic Testing Data | GenomeWeb
The US Food and Drug Administration is considering relabeling the widely prescribed anticoagulant Plavix with genetic information that could help identify best responders and help physicians make more informed prescribing decisions.
If the FDA goes through with the move, it would be the second anticoagulant after warfarin to have its label updated in such a way.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.